Relationship of 25（OH）D3 and liver inflammatory stage with the efficacy of antiviral therapy

doi:10.3969/j.issn.1673-8640.2022.07.006

Abstract

Abstract:

Objective To investigate the relationship between serum 25-hydroxyvitamin D₃ [25（OH）D₃] levels and the efficacy of antiviral therapy and liver inflammatory stage in patients with chronic hepatitis B（CHB）. Methods Totally,120 patients with CHB were enrolled and classified into auxiliary group（65 cases） and conventional group（55 cases）. They were classified into stage G1 group（12 cases）,stage G2 group（54 cases）,stage G3 group（39 cases） and stage G4 group（15 cases） according to the Scheuer scores of liver inflammatory stages. Pearson or Spearman correlation analysis was used to assess the correlation between the indicators. Results The differences in the rates of hepatitis B virus（HBV） DNA and hepatitis B e antigen（HBeAg） conversion between conventional and auxiliary groups at 12 weeks of treatment had no statistical significance（P>0.05）,and the differences in the rates of HBV DNA and HBeAg conversion at 24 weeks of treatment were statistically significant（P<0.05）. The difference in serum 25（OH）D₃ levels between auxiliary and conventional groups before treatment was not statistically significant（P>0.05）. After 24 weeks of treatment,serum 25（OH）D₃ levels in the 2 groups were higher than those before treatment（P<0.01）,and those of auxiliary group were higher than those in conventional group（P<0.001）. Serum interferon-gamma（INF-γ）,interleukin-6（IL-6） and tumor necrosis factor-alpha（TNF-α） levels were increased with the increasing liver inflammatory stages in CHB patients（P<0.05）,and serum 25（OH）D₃ levels were decreased with the increasing liver inflammatory stages（P<0.05）. Spearman correlation analysis showed that 25（OH）D₃ was negatively correlated with liver inflammatory stage（r=-0.715,P<0.001）. Pearson correlation analysis showed that 25（OH）D₃ was negatively correlated with IL-6 and TNF-α（r=-0.262 and -0.216,P<0.05） and had no correlation with INF-γ（r=-0.053,P>0.05）. Conclusions Serum 25（OH）D₃ levels in CHB patients are related with liver inflammatory stage and antiviral therapy efficacy.

Key words: 25-Hydroxyvitamin D₃, Hepatitis B virus, Liver inflammatory stage, Chronic hepatitis B

CLC Number:

R446.1

LIU Yang, GENG Kunjing, LI Hongjiang, SHI Haoxi, CHEN Sisi. Relationship of 25（OH）D₃ and liver inflammatory stage with the efficacy of antiviral therapy[J]. Laboratory Medicine, 2022, 37(7): 628-631.

Figures/Tables 2

References 16

[1]	ASRANI S K, DEVARBHAVI H, EATON J, et al. Burden of liver diseases in the world[J]. J Hepatol, 2019, 70(1):151-171. DOI URL
[2]	慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 中华临床感染病杂志, 2019, 12(4):241-252.
[3]	孙乐科, 吴俭. 维生素D对脓毒症小鼠炎症的抑制作用[J]. 江西医药, 2017, 52(1):45-47.
[4]	张利娟, 童巧霞. 慢性乙型肝炎肝纤维化患者血清25羟维生素D3水平临床研究[J]. 中华疾病控制杂志, 2018, 22(10):1016-1019.
[5]	皮小芳, 周红宇, 阳学风. 维生素D与肝纤维化关系研究进展[J]. 临床消化病杂志, 2018, 30(5):329-332.
[6]	耿坤静, 刘洋, 陈思思, 等. CHB患者血清25(OH)D_3水平与肝脏炎症活动度及纤维化程度的相关性分析[J]. 标记免疫分析与临床, 2021, 28(8):1371-1374.
[7]	MOHAMED A A, ABDO S, SAID E, et al. Serum vitamin D levels in chronic hepatitis B patients before and during treatment[J]. Infect Disord Drug Targets, 2020, 20(6):840-847. DOI URL
[8]	王贵强, 王福生, 庄辉, 等. 慢性乙型肝炎防治指南(2019年版)[J]. 中国病毒病杂志, 2020, 10(1):1-25.
[9]	陈成伟, 陈从新, 陈士俊, 等. 核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理[J]. 传染病信息, 2013, 26(1):1-9.
[10]	柯昌征, 刘平, 陈丽娥, 等. 乙型肝炎患者维生素D缺乏的相关研究[J]. 中西医结合肝病杂志, 2015, 25(2):83-85.
[11]	HOAN N X, TONG H V, SONG L H, et al. Vitamin D deficiency and hepatitis viruses-associated liver diseases:a literature review[J]. World J Gastroenterol, 2018, 24(4):445-460. DOI URL
[12]	陈丽萍, 周建. 维生素D₃联合复方甘草酸苷恩替卡韦治疗慢性乙型肝炎患者的临床研究[J]. 山西医药杂志, 2018, 47(22):2654-2657.
[13]	徐静, 李传杰, 王亮亮, 等. 维生素D3联合恩替卡韦对乙型肝炎肝硬化代偿期患者外周血T淋巴细胞水平及肝纤维化指标的影响[J]. 肝脏, 2019, 24(7):795-798.
[14]	AKCAM F Z, TIGLI A, KAYA O, et al. Cytokine levels and histopathology in chronic hepatitis B and chronic hepatitis C[J]. J Interferon Cytokine Res, 2012, 32(12):570-574. DOI URL
[15]	FARNIK H, BOJUNGA J, BERGER A, et al. Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients[J]. Hepatology, 2013, 58(4):1270-1276. DOI URL
[16]	MORA J R, IWATA M, VON ANDRIAN U H. Vitamin effects on the immune system:vitamins A and D take centre stage[J]. Nat Rev Immunol, 2008, 8(9):685-698. DOI URL

组别	例数	25（OH）D₃/（nmol/L）		t值	P值
组别	例数	治疗前	治疗24周	t值	P值
辅助治疗组	65	17.86±6.65	29.46±10.46	7.545	<0.001
常规治疗组	55	17.42±6.52	21.25±5.65	3.292	0.001
t值		0.364	5.211
P值		0.716	<0.001

组别	例数	25（OH）D₃/（nmol/L）		t值	P值
组别	例数	治疗前	治疗24周	t值	P值
辅助治疗组	65	17.86±6.65	29.46±10.46	7.545	<0.001
常规治疗组	55	17.42±6.52	21.25±5.65	3.292	0.001
t值		0.364	5.211
P值		0.716	<0.001

肝脏炎症分期	例数	25（OH）D₃/（nmol/L）	INF-γ/（pg/mL）	IL-6/（pg/mL）	TNF-α/（pg/mL）
G1期	12	29.28±10.25	25.65±5.89	124.56±15.59	15.36±2.54
G2期	54	23.68±11.76^*	32.78±8.67^*	195.65±16.85^*	21.74±4.31^*
G3期	39	18.13±6.63^*#	45.54±10.16^*#	232.44±21.17^*#	35.68±6.65^*#
G4期	15	13.13±4.29^*#△	61.19±12.08^*#△	320.33±25.52^*#△	58.77±9.56^*#△
F值		9.131	49.448	261.343	191.837
P值		<0.001	<0.001	<0.001	<0.001

肝脏炎症分期	例数	25（OH）D₃/（nmol/L）	INF-γ/（pg/mL）	IL-6/（pg/mL）	TNF-α/（pg/mL）
G1期	12	29.28±10.25	25.65±5.89	124.56±15.59	15.36±2.54
G2期	54	23.68±11.76^*	32.78±8.67^*	195.65±16.85^*	21.74±4.31^*
G3期	39	18.13±6.63^*#	45.54±10.16^*#	232.44±21.17^*#	35.68±6.65^*#
G4期	15	13.13±4.29^*#△	61.19±12.08^*#△	320.33±25.52^*#△	58.77±9.56^*#△
F值		9.131	49.448	261.343	191.837
P值		<0.001	<0.001	<0.001	<0.001

Relationship of 25（OH）D₃ and liver inflammatory stage with the efficacy of antiviral therapy

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 16

Related Articles 15

Recommended Articles

Metrics

[1]	ZHANG Ying, JING Lijuan, LI Li. Relationship between the expression of miR-138 in peripheral blood mononuclear cells of hepatitis B virus proliferation in carriers [J]. Laboratory Medicine, 2023, 38(6): 559-562.
[2]	MA Yanting, SU Xi, HUANG Fei, WANG Mengxian, SHEN Minna, ZHANG Chunyan, WANG Beili, PAN Baishen, GUO Wei. Clinical role of HBV RNA detection in chronic hepatitis B [J]. Laboratory Medicine, 2022, 37(1): 72-77.
[3]	LI Caidong, ZHANG Xuqiang, LEI Zhiping, CHEN Qiaoli, CHEN Lu, TIAN Pengfei, DUAN Zhengjun. Clinical values of IL-1β,IL-6 and TNF-α in different clinical courses of chronic HBV infection [J]. Laboratory Medicine, 2021, 36(8): 790-794.
[4]	LIU Tingting, LIN Yuting, Mila , LI Xiaoqin. Correlation between serum IL-33 level and its gene polymorphism and the clinical outcome of HBV infection [J]. Laboratory Medicine, 2021, 36(11): 1101-1105.
[5]	SONG Hui, YANG Lan, XU Limin, SHEN Zhenhua, LIU Qianqian, LIU Xinghui. Influence and mechanism of hepatitis B virus on the expression of HOXA10 [J]. Laboratory Medicine, 2021, 36(11): 1172-1176.
[6]	YUAN Yongming, ZHANG Xiaoying, GU Chao, ZHANG Jue, SUN Xuehua. Analysis of hepatitis B virus S protein mutation in chronic hepatitis B and cirrhosis patients [J]. Laboratory Medicine, 2020, 35(5): 428-433.
[7]	GUO Ping, ZHUANG Lihua, CHEN Liting, WANG Jianbiao, WU Jianfeng. Roles of MCV,RDW and SAA in the progression of chronic hepatitis B [J]. Laboratory Medicine, 2020, 35(11): 1153-1157.
[8]	LIU Yang, ZHANG Zhiping, PENG Daorong, SONG Liuwei, GE Shengxiang, HAO Xiaoke, LIU Jiayun. Establishment and performance evaluation of chemiluminescent microparticle immunoassay for the determination of high concentration HbsAg [J]. Laboratory Medicine, 2020, 35(10): 1056-1061.
[9]	WANG Yingzhi, LIU Hua, WANG Wenjuan, GAO Feng, YANG Cuixia. Roles of serum microRNA-122 and microRNA-155 in patients with chronic hepatitis B [J]. Laboratory Medicine, 2019, 34(8): 691-695.
[10]	YU Xiaochun, HU Xujiao, ZHANG Jiaqing, GUO Leilei. Roles of HA,Ⅳ-C,APRI and Fib-4 in the diagnosis of hepatitis B-related liver fibrosis [J]. Laboratory Medicine, 2019, 34(6): 539-542.
[11]	JIANG Lingli, XIAO Yanqun, WANG Xueliang, BAO Yun, YANG Yixiao, WANG Hualiang. Development and application of external quality assessment research material for YMDD mutation detection of hepatitis B virus [J]. Laboratory Medicine, 2019, 34(2): 176-179.
[12]	GAO Wanqin, ZHANG Qin, ZHU Lin, WU Bin, HE Wentao, ZHANG Tinglu, ZHAO Changxin. Analysis of genotyping and 6 nucleosides' resistance of HBV in patients with chronic hepatitis B [J]. Laboratory Medicine, 2019, 34(11): 994-997.
[13]	LUO Qingxin, CHEN Kaiting, LAN Yanling, MO Xin, CHEN Jiaqiang. Additive effect of serum 25-hydroxyvitamin D₃ in the treatment of depression [J]. Laboratory Medicine, 2018, 33(6): 491-494.
[14]	ZHU Jun, ZHU Yuqing, ZHU Lingfeng, JIANG Lingli, XU Chong. Flow fluorescent dot matrix technique for hepatitis B virus genotyping [J]. Laboratory Medicine, 2018, 33(5): 437-441.
[15]	HOU Li, YU Lu, NIU Yao, ZHANG Yuan, WANG Liang. Role of noninvasive diagnostic model for liver fibrosis in patients with chronic hepatitis B [J]. Laboratory Medicine, 2018, 33(10): 888-893.